专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US10456293B2 Ophthalmic system for sustained release of drug to eye 有权
公开(公告)号：US10456293B2
公开(公告)日：2019-10-29
申请号：US15694079
申请日：2017-09-01
申请人： ForSight Vision5, Inc.
发明人： Anne Brody Rubin , Yair Alster , Cary J. Reich
IPC分类号： A61F9/00
摘要： Disclosed is an ocular device including a first structure formed of a first material providing a first shape to the ocular device prior to positioning the ocular device on the surface of the eye, a second structure formed of a second, different material having a tubular structure and a lumen through which the first structure extends, and at least one therapeutic agent is dispersed within the second material of the second structure. The first shape of the ocular device conforms to a second, different shape after positioning the ocular device on the surface of the eye. Upon being removed from the eye, the ocular device retains the second shape or changes to a third shape different from both the first shape and the second shape. Related apparatus, systems and method are described.

2. 发明授权

US10004636B2 Anterior segment drug delivery 有权
公开(公告)号：US10004636B2
公开(公告)日：2018-06-26
申请号：US15230275
申请日：2016-08-05
申请人： Forsight Vision5, Inc.
发明人： Yair Alster , Eugene de Juan, Jr. , Cary J. Reich , Stephen Boyd , David Sierra , Jose D. Alejandro , K. Angela Macfarlane , Douglas Sutton
IPC分类号： A61F9/00 , A61M35/00 , A61K9/00 , A61K31/19 , A61K31/407 , A61K31/4178 , A61K31/5377 , A61K31/5415 , A61K31/43 , A61K31/55 , A61K31/557 , A61K31/5575 , A61K31/56 , A61K31/568 , A61K31/573 , A61K31/58 , A61K31/7036 , A61K38/00 , A61M31/00 , A61K31/335
CPC分类号： A61F9/0026 , A61F9/0017 , A61K9/0051 , A61K31/19 , A61K31/335 , A61K31/407 , A61K31/4178 , A61K31/43 , A61K31/5377 , A61K31/5415 , A61K31/55 , A61K31/557 , A61K31/5575 , A61K31/56 , A61K31/568 , A61K31/573 , A61K31/58 , A61K31/7036 , A61K38/00 , A61M31/002
摘要： A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.

3. 发明申请

US20180092926A1 Bimatoprost Ocular Silicone Inserts and Methods of Use Thereof 审中-公开
公开(公告)号：US20180092926A1
公开(公告)日：2018-04-05
申请号：US15725145
申请日：2017-10-04
申请人： ForSight Vision5, Inc.
发明人： Cary J. Reich , Carlos Schuler , Qiang Ye , Logan Stark , Rachna Jain
IPC分类号： A61K31/5575 , A61L27/18 , A61L27/54 , A61L27/48 , A61F9/00 , A61K47/34 , A61K9/70 , A61K9/00 , C08L83/04
CPC分类号： A61K31/5575 , A61F9/0017 , A61K9/0051 , A61K9/70 , A61K47/34 , A61L27/18 , A61L27/48 , A61L27/54 , C08L83/04
摘要： The present invention is directed to compositions of bimatoprost, processes of preparing these compositions, devices comprising these compositions, and methods of lowering intraocular pressure.

4. 发明授权

US10835416B2 Ocular insert apparatus and methods 有权
公开(公告)号：US10835416B2
公开(公告)日：2020-11-17
申请号：US15905525
申请日：2018-02-26
申请人： ForSight Vision5, Inc.
发明人： Eugene de Juan , Yair Alster , Cary J. Reich , K. Angela Macfarlane , Janelle Chang , Stephen Boyd , David Sierra , Jose D. Alejandro , Douglas Sutton , Alexander J. Gould
IPC分类号： A61F9/00 , A61K9/00 , A61B17/00 , A61L27/02 , A61L27/16 , A61K47/34
CPC分类号： A61F9/0017 , A61B17/00234 , A61K9/0051 , A61L27/025 , A61L27/16 , A61K47/34
摘要： A comfortable insert comprises a retention structure sized for placement under the eyelids and along at least a portion of conjunctival sac of the upper and lower lids of the eye. The retention structure resists deflection when placed in the conjunctival sac of the eye and to guide the insert along the sac when the eye moves. The retention structure can be configured in many ways to provide the resistance to deflection and may comprise a hoop strength so as to urge the retention structure outward and inhibit movement of the retention structure toward the cornea. The insert may move rotationally with deflection along the conjunctival sac, and may comprise a retention structure having a cross sectional dimension sized to fit within folds of the conjunctiva. The insert may comprise a release mechanism and therapeutic agent to release therapeutic amounts of the therapeutic agent for an extended time.

5. 发明申请

US20190105198A1 ANTERIOR SEGMENT DRUG DELIVERY 审中-公开
公开(公告)号：US20190105198A1
公开(公告)日：2019-04-11
申请号：US16003857
申请日：2018-06-08
申请人： ForSight Vision5, Inc.
发明人： Yair Alster , Eugene de Juan, JR. , Cary J. Reich , Stephen Boyd , David Sierra , Jose D. Alejandro , K. Angela Macfarlane , Douglas Sutton
IPC分类号： A61F9/00 , A61K31/55 , A61K31/5377 , A61K31/5575 , A61K31/407 , A61K31/58 , A61K38/00 , A61K31/5415 , A61K31/43 , A61K31/19 , A61K31/557 , A61K31/4178 , A61K31/7036 , A61K31/573 , A61K31/568 , A61K9/00 , A61M31/00 , A61K31/335 , A61K31/56
摘要： A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.

6. 发明申请

US20160243291A1 Formulations and Methods for Increasing or Reducing Mucus 审中-公开
标题翻译：增加或减少粘液的制剂和方法
公开(公告)号：US20160243291A1
公开(公告)日：2016-08-25
申请号：US15027573
申请日：2014-10-13
申请人： FORSIGHT VISION5, INC.
发明人： Cary J. Reich , K. Angela Macfarlane , Yair Alster , Logan Stark
IPC分类号： A61L31/12 , A61F9/00 , A61L31/16
CPC分类号： A61L31/125 , A61F9/0017 , A61K9/0051 , A61L31/16 , A61L2430/16
摘要： The present disclosure is directed to a pharmaceutical delivery device useful for the treatment of ocular diseases and disorders through sustained release of therapeutic doses of a pharmaceutical agent, while increasing or reducing formation and/or accumulation of mucus.
摘要翻译：本公开涉及用于通过持续释放治疗剂量的药剂来治疗眼部疾病和病症的药物递送装置，同时增加或减少粘液的形成和/或积聚。

7. 发明申请

US20140121612A1 Ophthalmic System for Sustained Release of Drug to Eye 有权
标题翻译：用于药物持续释放眼睛的眼科系统
公开(公告)号：US20140121612A1
公开(公告)日：2014-05-01
申请号：US14063571
申请日：2013-10-25
申请人： ForSight Vision5, Inc.
发明人： Anne Brody Rubin , Yair Alster , Cary J. Reich
IPC分类号： A61F9/00
CPC分类号： A61F9/0017 , A61F2250/0067 , Y10T156/1036
摘要： Disclosed is an ocular device including a first structure formed of a first material providing a first shape to the ocular device prior to positioning the ocular device on the surface of the eye, a second structure formed of a second, different material having a tubular structure and a lumen through which the first structure extends, and at least one therapeutic agent is dispersed within the second material of the second structure. The first shape of the ocular device conforms to a second, different shape after positioning the ocular device on the surface of the eye. Upon being removed from the eye, the ocular device retains the second shape or changes to a third shape different from both the first shape and the second shape. Related apparatus, systems and method are described.
摘要翻译：公开了一种眼部装置，其包括第一结构，该第一结构由在将眼睛装置定位在眼睛的表面上之前向眼睛装置提供第一形状的第一材料形成，第二结构由具有管状结构的第二不同材料形成，第一结构延伸穿过的内腔，以及至少一种治疗剂分散在第二结构的第二材料内。眼睛装置的第一种形状在将眼睛装置定位在眼睛的表面上之后符合第二种不同的形状。当从眼睛移除时，眼睛装置保持第二形状或改变为不同于第一形状和第二形状的第三形状。描述相关装置，系统和方法。

8. 发明申请

US20210128351A1 ANTERIOR SEGMENT DRUG DELIVERY 有权
公开(公告)号：US20210128351A1
公开(公告)日：2021-05-06
申请号：US16930678
申请日：2020-07-16
申请人： ForSight Vision5, Inc.
发明人： Yair Alster , Eugene de Juan, JR. , Cary J. Reich , Stephen Boyd , David Sierra , Jose D. Alejandro , K. Angela Macfarlane , Douglas Sutton
IPC分类号： A61F9/00 , A61K9/00 , A61K31/19 , A61K31/407 , A61K31/4178 , A61K31/5377 , A61K31/5415 , A61K31/43 , A61K31/55 , A61K31/557 , A61K31/5575 , A61K31/56 , A61K31/568 , A61K31/573 , A61K31/58 , A61K31/7036 , A61K38/00 , A61M31/00 , A61K31/335
摘要： A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.

9. 发明申请

US20190142842A1 Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent 审中-公开
公开(公告)号：US20190142842A1
公开(公告)日：2019-05-16
申请号：US16243842
申请日：2019-01-09
申请人： ForSight Vision5, Inc.
发明人： Logan Stark , Rachna Jain , Ravi Srinivasan , Cary J. Reich , Carlos Schuler
IPC分类号： A61K31/5575 , A61K9/00 , A61K47/34
摘要： The present disclosure includes compositions of a semi-crystalline or crystalline pharmaceutically active agent dispersed in a polymer matrix, in which the active agent is less degraded and, therefore, has lower level of impurities. The present disclosure further includes a method of reducing or preventing physical and chemical degradation of a semi-crystalline or crystalline active agent pharmaceutically active agent dispersed in a polymer matrix. A method of preparation of the composition is also included in this disclosure.

10. 发明申请

US20180085254A1 Ophthalmic System For Sustained Release Of Drug To Eye 审中-公开
公开(公告)号：US20180085254A1
公开(公告)日：2018-03-29
申请号：US15694079
申请日：2017-09-01
申请人： ForSight Vision5, Inc.
发明人： Anne Brody Rubin , Yair Alster , Cary J. Reich
IPC分类号： A61F9/00
CPC分类号： A61F9/0017 , A61F2250/0067
摘要： Disclosed is an ocular device including a first structure formed of a first material providing a first shape to the ocular device prior to positioning the ocular device on the surface of the eye, a second structure formed of a second, different material having a tubular structure and a lumen through which the first structure extends, and at least one therapeutic agent is dispersed within the second material of the second structure. The first shape of the ocular device conforms to a second, different shape after positioning the ocular device on the surface of the eye. Upon being removed from the eye, the ocular device retains the second shape or changes to a third shape different from both the first shape and the second shape. Related apparatus, systems and method are described.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式